RSMDF ResMed Inc. Earnings Preview April 30, 2026

ResMed Inc. (RSMDF) will report fiscal Q3 earnings on April 30, 2026, after market close. Analysts expect earnings per share of $0.2802 and revenue of $1.42 billion. The medical device and cloud software company has beaten earnings estimates in three of the last four quarters, showing consistent operational strength. With a market cap of $36.26 billion and a Meyka AI grade of B+, investors are watching closely to see if ResMed can maintain its momentum in sleep and respiratory care markets. The earnings preview reveals important trends in profitability, cash flow, and growth that will shape investor sentiment heading into the second half of 2026.

What Analysts Expect from ResMed Earnings

Analysts project RSMDF will deliver $0.2802 earnings per share and $1.42 billion in revenue for the quarter ending April 28, 2026. These estimates represent modest growth compared to the previous quarter’s actual results. The company has demonstrated a strong track record of meeting or exceeding expectations.

EPS Estimate Analysis

The $0.2802 EPS estimate is slightly higher than the prior quarter’s $0.281 actual result. This suggests analysts expect stable profitability despite potential headwinds. The company’s net profit margin of 27.5% remains healthy, indicating strong cost management and operational efficiency in its medical device and software divisions.

Revenue Estimate Breakdown

The $1.42 billion revenue estimate compares favorably to the previous quarter’s $1.423 billion actual revenue. This represents a slight sequential decline, which is typical for ResMed’s seasonal patterns. Year-over-year growth remains positive, driven by demand for sleep apnea devices and cloud-based healthcare software solutions.

Consensus Outlook

Wall Street maintains a cautiously optimistic stance on ResMed. The company’s ability to grow earnings faster than revenue (37.6% net income growth versus 9.8% revenue growth) demonstrates improving operational leverage and margin expansion in its Software-as-a-Service segment.

Historical Earnings Performance and Beat/Miss Pattern

ResMed has delivered impressive results over the past four quarters, beating earnings estimates in three of four reports. This track record suggests management’s guidance is conservative and execution remains strong across business segments.

Recent Quarter Results

In Q2 2026 (January 29 earnings), ResMed reported $0.281 EPS versus $0.2748 estimate, beating by $0.0062 per share. Revenue came in at $1.423 billion versus $1.402 billion estimate, also beating expectations. The October 2025 quarter showed $0.255 EPS versus $0.252 estimate, another beat. This consistent outperformance suggests the company has strong operational discipline.

Beat/Miss Probability

Based on the three-of-four beat pattern, investors should expect ResMed has a 75% probability of beating the $0.2802 EPS estimate. The company’s conservative guidance and strong execution in sleep and respiratory care markets support this outlook. However, the revenue estimate appears more challenging given seasonal headwinds.

Earnings Trend Direction

ResMed’s earnings trajectory shows strong improvement. EPS grew from $0.2582 in Q1 to $0.281 in Q2, representing 8.8% sequential growth. This upward trend reflects margin expansion and operational efficiency gains, particularly in the high-margin software segment.

Key Metrics and What to Watch

Investors should focus on several critical metrics during the earnings call to assess ResMed’s health and growth prospects. These indicators will reveal whether the company can sustain its momentum in competitive healthcare markets.

Profitability and Margin Expansion

ResMed’s gross profit margin of 61% and operating margin of 33.8% rank among the best in medical device manufacturing. Watch for any margin compression from supply chain costs or pricing pressure. The company’s net profit margin of 27.5% demonstrates pricing power in its sleep and respiratory care products. Management should discuss how software revenue, which carries higher margins, is growing relative to hardware sales.

Cash Flow Generation

Operating cash flow of $13.07 per share and free cash flow of $12.21 per share show strong cash generation. The company’s current ratio of 3.06 indicates excellent liquidity. Investors should monitor whether free cash flow growth continues at the 29.2% rate seen in recent periods, which would support dividend increases and potential acquisitions.

Software Segment Performance

The Software-as-a-Service segment is critical to ResMed’s future. Cloud-based solutions like AirView, myAir, and MatrixCare drive recurring revenue and higher margins. Listen for updates on software customer additions, retention rates, and average revenue per user. This segment’s growth will determine whether ResMed can maintain its 37.6% net income growth rate.

Geographic and Product Mix

ResMed operates in approximately 140 countries. Management should discuss performance in key markets like North America, Europe, and Asia-Pacific. Watch for commentary on sleep apnea device adoption rates, ventilator demand, and home healthcare software penetration. Any shifts in product mix toward higher-margin software will be positive for earnings quality.

Meyka AI Grade and Investment Implications

Meyka AI rates RSMDF with a grade of B+, reflecting solid fundamentals and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade suggests ResMed is a quality company trading at reasonable valuations relative to growth.

What the B+ Grade Means

The B+ rating indicates ResMed scores well on profitability metrics (ROE of 24.8%, ROA of 17.5%) and growth indicators. The company’s PEG ratio of 1.10 suggests the stock is fairly valued relative to earnings growth. However, the PE ratio of 21.3 is elevated compared to the broader market, reflecting investor confidence in future growth. The grade reflects balanced risk and reward for long-term investors.

Valuation Context

ResMed trades at 5.84x sales and 21.3x earnings, which is premium to many medical device peers. This valuation is justified by the company’s 37.6% net income growth and expanding software revenue. The dividend yield of 1.07% provides modest income while the company reinvests profits into growth initiatives. Investors should view the B+ grade as confirmation that current valuations are reasonable for a healthcare company with ResMed’s growth profile.

Risk Factors to Monitor

The grade does not guarantee future performance. Investors should watch for regulatory changes in healthcare reimbursement, competitive pressures from larger medical device companies, and execution risks in software integration. The company’s debt-to-equity ratio of 0.16 is conservative, providing financial flexibility to weather downturns or invest in acquisitions.

Final Thoughts

ResMed enters its April 30 earnings report with strong momentum and a history of beating expectations. Analysts project $0.2802 EPS and $1.42 billion in revenue. The main focus is margin expansion from software growth and operational efficiency. With a B+ grade, solid cash flow, and a $36.26 billion market cap, ResMed is well-positioned in healthcare technology. Investors should monitor software performance, cash flow trends, and full-year guidance to evaluate the company’s growth trajectory.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.